75 related articles for article (PubMed ID: 16020978)
1. A phase I study of docetaxel, Cisplatin, 5-Fluorouracil and leucovorin.
Mulcahy MF; Loehrer PJ; Meropol NJ; Rademaker AW; Benson Iii AB
Oncology; 2005; 68(4-6):479-84. PubMed ID: 16020978
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose-escalating study of 24-h continuous infusion of 5-fluorouracil in combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer.
Wang B; Zhang W; Hong X; Guo Y; Li J
Cancer Chemother Pharmacol; 2009 Jan; 63(2):213-8. PubMed ID: 18343924
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
5. A phase I-phase II study of vinorelbine with cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
Masters GA; Drinkard LC; Hoffman PC; Lane N; Watson S; Samuels BL; Bitran JD; Golomb HM; Vokes EE
Cancer J Sci Am; 1995; 1(4):288-94. PubMed ID: 9166490
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
Mani S; Rudin CM; Kunkel K; Holmlund JT; Geary RS; Kindler HL; Dorr FA; Ratain MJ
Clin Cancer Res; 2002 Apr; 8(4):1042-8. PubMed ID: 11948111
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of ambulatory infusional delivery of a multidrug regimen: cisplatin, 5-fluorouracil and leucovorin (PFL) +/- etoposide.
Lokich J; Anderson N; Moore C; Bern M; Coco F; Dow E; Zipoli T; Gonzalves L
J Infus Chemother; 1996; 6(1):43-6. PubMed ID: 8748007
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
Di Bartolomeo M; Buzzoni R; Mariani L; Ferrario E; Katia D; Gevorgyan A; Zilembo N; Bordonaro R; Bochicchio AM; Massidda B; Ardizzoia A; Marini G; Aitini E; Schieppati G; Comella G; Pinotti G; Palazzo S; Cicero G; Bajetta E; ; Villa E; Fagnani D; Reguzzoni G; Agostana B; Oliani C; Kildani B; Duro M; Botta M; Mozzana R; Mantovani G
Oncology; 2006; 71(5-6):341-6. PubMed ID: 17855795
[TBL] [Abstract][Full Text] [Related]
9. Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial.
Al-Batran SE; Kerber A; Atmaca A; Dechow C; Reitsamer E; Schmidt S; Kolassa Y; Neumann A; Weidmann E; Hartmann JT; Jäger E
Onkologie; 2007 Feb; 30(1-2):29-34. PubMed ID: 17264523
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck.
Tsukuda M; Mikami Y; Tanigaki Y; Katori H; Horiuchi C; Ikeda Y; Taguchi T; Ono M; Yoshida T; Sakuma Y; Aikoh K
Int J Clin Oncol; 2004 Jun; 9(3):161-6. PubMed ID: 15221599
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
Yamada Y; Ohtsu A; Boku N; Miyata Y; Shimada Y; Doi T; Muro K; Muto M; Hamaguchi T; Mera K; Yano T; Tanigawara Y; Shirao K
Jpn J Clin Oncol; 2006 Apr; 36(4):218-23. PubMed ID: 16684860
[TBL] [Abstract][Full Text] [Related]
12. A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
Van Den Neste E; de Valeriola D; Kerger J; Bleiberg H; Kusenda Z; Brassinne C; Bartholomeus S; Selleslags J; Hennebert P; Wythouck H; Cazenave I; Lefresne-Soulas F; Piccart M
Clin Cancer Res; 2000 Jan; 6(1):64-71. PubMed ID: 10656433
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck.
Hitt R; Jimeno A; Millán JM; Castellano D; Cortés-Funes H
Cancer; 2004 Aug; 101(4):768-75. PubMed ID: 15305408
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design.
Vokes EE; Drinkard LC; Samuels BL; Hoffman PC; Watson S; Bitran JD; Haraf DJ; Ferguson MF; Golomb HM
Semin Oncol; 1994 Oct; 21(5 Suppl 10):79-83; discussion 83-4. PubMed ID: 7973772
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel in combination with fluorouracil for advanced solid tumors.
Burris HA
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):50-2. PubMed ID: 9364544
[TBL] [Abstract][Full Text] [Related]
16. Infusional 5-fluorouracil/leucovorin plus paclitaxel and cisplatin in the first-line treatment of metastatic breast cancer: results of a phase II study.
Klaassen U; Wilke H; Müller C; Borquez D; Harstrick A; Seeber S
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-58-S17-60. PubMed ID: 9374095
[TBL] [Abstract][Full Text] [Related]
17. Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine.
Marshall JL; Richmond E; DeLap RJ
Clin Cancer Res; 1996 Sep; 2(9):1475-80. PubMed ID: 9816323
[TBL] [Abstract][Full Text] [Related]
18. Intensified bimonthly cisplatin with bolus 5-fluorouracil, continuous 5-fluorouracil and high-dose leucovorin (LV5FU2) in Patients with advanced gastrointestinal carcinomas: a phase I dose-finding and pharmacokinetic study.
Bamias A; Syrigos K; Fountzilas G; Tzamakou E; Soulti K; Karavasilis V; Alamanos Y; Christodoulou C; Pavlidis N
Am J Clin Oncol; 2004 Oct; 27(5):465-71. PubMed ID: 15596912
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
[TBL] [Abstract][Full Text] [Related]
20. Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial).
Duffour J; Bouché O; Rougier P; Milan C; Bedenne L; Seitz JF; Buecher B; Legoux JL; Ducreux M; Vetter D; Raoul JL; François E; Ychou M
Anticancer Res; 2006; 26(5B):3877-83. PubMed ID: 17094417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
